RxSight, Inc. Announces Chief Financial Officer Transition

Shelley Thunen, Chief Financial Officer of RxSight, Inc., is transitioning from her role, with her departure effective upon the appointment of her successor or January 31, 2026. She will provide consulting services to the company post-transition. Thunen will remain eligible for her 2025 annual cash bonus and will receive her base salary through her transition date. She will be paid a non-refundable retainer of $15,000 per month for January, February, and March 2026, if her consulting agreement is terminated by the company without cause before March 31, 2026. Her hourly rate for consulting services will be $500, and her outstanding stock options will continue to vest under their original terms until December 31, 2026, when the consulting agreement is set to end. The company expressed gratitude for her contributions, highlighting her role in guiding RxSight from a pre-commercial stage to its current market position, including its 2021 IPO.